Airway Disease clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States. Patients with COPD are routinely exposed to indoor and outdoor air pollution, which appears to cause escalation of their respiratory symptoms, a process called exacerbation, with resulting need to seek medical attention. This research plan proposes to evaluate the impact of lung immune cells in susceptibility to develop exacerbation through an experimental model of inhalational exposure using ambient levels of a component of air pollution (ozone) in COPD patients and longitudinal sampling of their lung immune cells.
San Francisco, California and other locations
Our lead scientists for Airway Disease research studies include Mehrdad Arjomandi, M.D..